Pharmacopsychiatry

Aims & Scope

Covering advances in the fi eld of psychotropic drugs, Pharmaco psychiatry provides psychiatrists, neuroscientists and clinicians with key clinical insights and describes new avenues of research and treatment.

The pharmacological and neurobiological bases of psychiatric disorders are discussed by presenting clinical and experimental research.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.2
2024	3.60

SJR (SCImago Journal Rank)

Year	Value
2024	0.943

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	86

Journal Rank

Year	Value
2024	5329

Journal Citation Indicator

Year	Value
2024	311

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  Citation: 824

  Authors: C., N., H., A., J., K., G., K., M., C., G., E., U., G., R., G., E., G., T., R., M., M., B., P., A., B., G., M., M., B., W., J., M., S., S., R., G., G., P.

• AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011

  Citation: 693

  Authors: C., P., N., A., O., K., M., M., C., G., E., U., E., H., G., U., T., M., B., B., P., B., J., M., S., R., G.

• The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans

  Citation: 421

  Authors: A.

• The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry

  Citation: 361

  Authors: P., C., S., G., I., M., H.-J., G., B., M. L., P., G.

• Course of the Manic-Depressive Cycle and Changes Caused by Treatments

  Citation: 352

  Authors: A., D., P., G., G., L.

• Biologically Active and Other Chemical Constituents of the Herb of<i>Hypericum perforatum</i>L.

  Citation: 280

  Authors: A., V.

• Proof of Efficacy of the Ginkgo Biloba Special Extract EGb 761 in Outpatients Suffering from Mild to Moderate Primary Degenerative Dementia of the Alzheimer Type or Multi-infarct Dementia

  Citation: 280

  Authors: S., W., K., W., R.

• The Revised Monoamine Theory of Depression: A Modulatory Role for Monoamines, Based on New Findings From Monoamine Depletion Experiments in Humans

  Citation: 279

  Authors: G., P., D.

• Adaptation of N-Methyl-D-Aspartate (NMDA) Receptors following Antidepressant Treatment: Implications for the Pharmacotherapy of Depression

  Citation: 278

  Authors: P., R., P., G., I., R.

• St. John's Wort in Mild to Moderate Depression: The Relevance of Hyperforin for the Clinical Efficacy

  Citation: 250

  Authors: G., C., T., M.

---